A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy

Treatments using immune checkpoint inhibitors such as pembrolizumab lead to immune mediated adverse effects including hemophagocytic lymphohistiocytosis (HLH). Herein, we present a case where HLH developed after pembrolizumab administration, which was treated using high dose prednisolone. He develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Hidenori, Koiwa, Tomohiro, Fujita, Akira, Suzuki, Takayuki, Tagashira, Amane, Iwasaki, Yoshinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260580/
https://www.ncbi.nlm.nih.gov/pubmed/32489850
http://dx.doi.org/10.1016/j.rmcr.2020.101097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260580/
https://www.ncbi.nlm.nih.gov/pubmed/32489850
http://dx.doi.org/10.1016/j.rmcr.2020.101097

Ejemplares similares